Trilogy Capital’s ARK Genomic Revolution ETF ARKG Stock Holding History

Trilogy Capital’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-11,394	Closed	-$328K	–	318
2024 Q1	$328K	Sell	11,394 -1,119	-9%	-$33.6K	0.02%	245
2023 Q4	$411K	Buy	+12,513	New	+$340K	0.03%	187
2023 Q3	–	Sell	-9,422	Closed	-$350K	–	258
2023 Q2	$350K	Buy	+9,422	New	+$296K	0.02%	202
2023 Q1	–	Sell	-10,268	Closed	-$290K	–	243
2022 Q4	$290K	Buy	+10,268	New	+$326K	0.02%	208

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Trilogy Capital's ARKG Position: Q2 2024 in Review

Trilogy Capital sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2024, closing a stake of 11,394 shares — an estimated $328K sold.

Trilogy Capital first reported a position in ARKG in Q4 2022 and held it in 4 quarters. The position peaked at $411K in Q4 2023. 261 funds tracked by Wall St. Rank hold ARKG as of Q2 2024.

Trilogy Capital reported no remaining ARK Genomic Revolution ETF position as of Q2 2024 after selling out during the quarter.
Trilogy Capital sold 11,394 ARK Genomic Revolution ETF shares in Q2 2024, an estimated $328K.
Trilogy Capital first reported a position in ARK Genomic Revolution ETF in Q4 2022 and held it in 4 quarters.
Trilogy Capital's ARK Genomic Revolution ETF position peaked at $411K in Q4 2023.
261 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2024.

Based on Trilogy Capital's 13F filing for Q2 2024, filed 23 Jul 2024.